Table 1.
Krauze Scoring System
| Prognostics Factor | Subgroups | Value for prognostic score |
|---|---|---|
| Independent Factors | ||
| Patient Age | >60 years | 1 |
| 50–60 years | 2 | |
| <50 years | 3 | |
| KPS | <50% | 1 |
| 50–70% | 2 | |
| >70% | 3 | |
| Histology | WHO Grade IV | 1 |
| WHO Grade III | 2 | |
| WHO Grade II | 3 | |
| Presence of symptoms | Documented neurological symptoms related to recurrence requiring steroid management | 1 |
| Documented neurologicalsymptoms relatedto recurrence or impending neuro symptoms | 2 | |
| No neurological symptoms related to recurrence | 3 | |
| Target Control | ||
| Tumor size (GTV) | >500 cm3 or diffuse disease/ gliomatosis | 1 |
| 20–500 cm3 | 2 | |
| <20 cm3 | 3 | |
| Tumor recurrencelocation withrespect to originaltreatment field (60Gy isodose line) | <1 cm away or completelywithin the original treatment field | 1 |
| 1–3 cm away | 2 | |
| >3 cm away | 3 | |
| Diffuse disease present | Multiple T1 gadolinium- enhancing lesions | 1 |
| T2 FLAIR diffuse involvement | 2 | |
| None (localized recurrence only) | 3 | |
| Anticipated Toxicity Risk | ||
| OAR location with respect to recurrence area | >1 cm away from or in the recurrence area | 1 |
| 1–3 cm away from recurrence area | 2 | |
| >3 cm away from the recurrence area | 3 | |
| OAR dose contribution from original treatmenta | <90% dose allowed as per Quantec dose constraints | 1 |
| Within +/− 10% of dose allowed as per Quantec constraints | 2 | |
| Exceeds >10% over the Quantec constraints | 3 | |
| Disease free interval from initial treatment with radiation | <1 year | 1 |
| 1–3 years | 2 | |
| >3 years | 3 | |
aOAR QUANTEC dose constraints: Chiasm: 55Gy, Optic Nerves: 55Gy, Brain Stem: 54 Gy. WHO World Health Organisation